Researchers at the Cleveland Clinic have confirmed that in order to treat prostate cancer, brachytherapy and prostatectomy surgery is less toxic and cost-effective when compared to external beam radiation or radiotherapy.
Each year, around 250,000 U.S. men are being diagnosed with prostate cancer, thereby increasing the demand for the right treatment of cancer. Three primary treatment options are recommended for head-on diagnosis of low-to-moderate-risk prostate cancer such as internal seed implantation or external beam radiations, and prostatectomy surgery using robotics or laparoscopy techniques.
Prostatectomy surgery and brachytherapy were believed to be effective. The wide range of benefits with robotic prostatectomy surpasses that of both internal and external radiations, according to Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and minimally invasive surgery at The Mount Sinai Medical Center.
Following successful achievements with robotic prostatectomy procedures, Dr. David Samadi illustrated the fact that robotic surgery is a superior approach to treating prostate cancer. Robotic prostatectomy is a unique procedure where the cancerous prostate can be removed completely. The minimally invasive procedure facilitates excellent visibility during operation. This procedure entails only less amount of blood. In addition, the robotic tools' access to prostrate easily by introducing CO2 gas in the abdomen that also facilitates the movement of tools in and around the delicate tissue and nerve bundles enclosing the part.